Novo Nordisk denied interim stay in Indian semaglutide patent appeal
By Freny Patel ( December 12, 2025, 10:08 GMT | Insight) -- Novo Nordisk failed to secure interim relief before an Indian court, allowing Dr. Reddy’s Laboratories to continue manufacturing and exporting semaglutide amid a credible challenge to patent validity. In a setback for global pharmaceutical giant Novo Nordisk, a division bench of the Delhi High Court on Friday declined to grant an interim stay on an order allowing Dr. Reddy’s Laboratories to manufacture the active ingredient semaglutide in India for export markets....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.